Private equity firm GTCR announced today that it signed an agreement for Corza Medical to sell its Biosurgery business unit.

GTCR initially formed Corza Medical in 2019.

EQT to acquire Corza Biosurgery, a premier biosurgery business built around TachoSil, a leading hemostat and sealant patch used across a wide range of surgical specialties TachoSil supports improved ...

Headquartered in Boulder, Colorado, Corza Medical is a medical tech firm. Following the transaction, GTCR will retain ...

WESTWOOD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Corza Medical ("Corza") announced strategic plans to directly sell TachoSil®, a best-in-class surgical fibrin sealant patch trusted by medical ...

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant ...

(RTTNews) - Japan's Takeda Pharmaceutical Company Ltd. (TAK) announced Monday that it has completed the previously announced sale of TachoSil Fibrin Sealant Patch to Corza Health, Inc. for 350 million ...

The European Commission said Wednesday that it has opened an investigation into the planned acquisition of surgical-patch product TachoSil -- owned by Takeda Pharmaceutical Co. -- by Johnson & Johnson ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

EQT will support TachoSil by investing in commercial acceleration, geographic expansion, and by building out a broader biosurgery platform through M&A; With the transaction, EQT X ...